Colonia Therapeutics' CEO argues that lentiviral delivery is ideal for oncology's required long-term persistence, while LNP delivery is better suited for autoimmune indications needing transient, multi-dose responses. This frames them as complementary technologies for different therapeutic "swim lanes" rather than as direct rivals in a zero-sum game.

While redosing may be an option for RNA-based in vivo CAR-Ts, viral vector-based platforms face a significant challenge. The potential for an immune response against the vector, a well-known issue in AAV gene therapy, could prevent subsequent doses and limit the long-term treatment strategy for these therapies.

Eli Lilly's recent deal-making reveals an aggressive, multi-modal strategy. It secured an AI partnership for obesity (Nimbus), invested in an AI platform for oncology (InduPro), and spent $1.2B acquiring Ventix Biosciences for its oral inflammation pipeline, demonstrating a broad approach to securing leadership in its focus areas.

Observing that allogeneic ('off-the-shelf') cell therapies have not yet achieved their expected impact, Kite Pharma is strategically investing in in vivo approaches. Through acquisitions and partnerships, they are focusing on technologies that edit cells directly within the body, which have shown promising 'autologous-like' results.

Despite excitement for in-vivo CAR-Ts, the high response rates and multi-year survival of current autologous therapies create a significant competitive moat. New modalities must not only match this efficacy but also prove long-term durability, a high bar that insulates incumbents in indications like multiple myeloma for the foreseeable future.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

While complex gene editing may be challenging in vivo, Colonia's platform presents a novel opportunity: targeting different immune cell types (e.g., T-cells and NK cells) with distinct payloads in a single treatment. This could create synergistic, multi-pronged attacks on tumors, a paradigm distinct from current ex vivo methods which focus on engineering a single cell type.

Within one week, Eli Lilly executed two massive deals: an $8.5B potential collaboration with Innovent for antibody therapeutics and a $2.4B acquisition of Orna Therapeutics for its circular RNA CAR-T platform. This signals an aggressive, multi-pronged strategy to dominate both established and next-generation therapeutic modalities.

Create Medicines chose LNP-delivered RNA for its in vivo platform to give physicians control. Unlike permanent lentiviral approaches, repeatable dosing allows for adapting to tumor antigen escape and managing durability and safety over time. This flexibility is a core strategic advantage for complex diseases like solid tumors.